CN108026173A - 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症 - Google Patents

通过联合阻断pd-1和cxcr4信号传导途径治疗癌症 Download PDF

Info

Publication number
CN108026173A
CN108026173A CN201680047043.2A CN201680047043A CN108026173A CN 108026173 A CN108026173 A CN 108026173A CN 201680047043 A CN201680047043 A CN 201680047043A CN 108026173 A CN108026173 A CN 108026173A
Authority
CN
China
Prior art keywords
antibody
cxcr4
antigen
cancer
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680047043.2A
Other languages
English (en)
Chinese (zh)
Inventor
J.M.卡达雷利
W.L.克莱门斯
G.S.克鲁格
D.E.罗佩斯德梅内泽斯
潘勤
P.D.波纳思
J.比亚莱特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN108026173A publication Critical patent/CN108026173A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680047043.2A 2015-06-12 2016-06-13 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症 Pending CN108026173A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562174931P 2015-06-12 2015-06-12
US62/174931 2015-06-12
PCT/US2016/037207 WO2016201425A1 (en) 2015-06-12 2016-06-13 Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways

Publications (1)

Publication Number Publication Date
CN108026173A true CN108026173A (zh) 2018-05-11

Family

ID=56194616

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680047043.2A Pending CN108026173A (zh) 2015-06-12 2016-06-13 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症

Country Status (9)

Country Link
US (1) US20180179282A1 (enExample)
EP (1) EP3307778A1 (enExample)
JP (1) JP2018516969A (enExample)
CN (1) CN108026173A (enExample)
BR (1) BR112017026189A2 (enExample)
CA (1) CA2989144A1 (enExample)
EA (1) EA201792522A1 (enExample)
MX (1) MX2017015811A (enExample)
WO (1) WO2016201425A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020135415A1 (zh) * 2018-12-24 2020-07-02 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途
CN113164600A (zh) * 2018-10-17 2021-07-23 百欧林纳克斯有限公司 转移性胰脏腺癌的治疗
CN115487146A (zh) * 2022-10-28 2022-12-20 宁夏医科大学 一种阻断cxcr4/pd-l1双信号的三药共递送纳米体系及其制备方法和应用
CN115960269A (zh) * 2023-01-30 2023-04-14 上海甲贝医药科技有限公司 一种重组长效人cxcr4&pd-1双靶点抗体融合蛋白及其制备方法
WO2024120084A1 (zh) * 2022-12-07 2024-06-13 宜明昂科生物医药技术（上海）股份有限公司 使用cd24抗体和pd-1-pd-l1通路阻断抗体的癌症联合疗法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019344B1 (ru) * 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
US9212224B2 (en) * 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US11357742B2 (en) 2015-12-14 2022-06-14 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
ES2935834T3 (es) 2015-12-22 2023-03-10 X4 Pharmaceuticals Inc Métodos para tratar enfermedad de inmunodeficiencia
US20190030023A1 (en) * 2016-01-22 2019-01-31 X4 Pharmaceuticals, Inc. Methods for treating cancer
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11332470B2 (en) 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
EP3548070A4 (en) * 2016-11-29 2020-07-22 Health Research, Inc. METHODS AND COMPOSITIONS FOR ANTI-CANCER THERAPY
MX2019011324A (es) * 2017-03-23 2020-01-21 Massachusetts Gen Hospital Bloqueo de cxcr4/cxcr7 y tratamiento de enfermedad asociada con el virus del papiloma humano.
US20190233524A1 (en) * 2017-09-18 2019-08-01 Tcm Biotech International Corp. Therapeutic combination and method for treating cancer
CN109517039B (zh) * 2017-09-20 2021-03-19 尚华医药科技(江西)有限公司 一种肽类化合物、其应用及含其的组合物
CN111465613A (zh) * 2017-11-07 2020-07-28 X4 制药有限公司 癌症生物标志物及其使用方法
CN112513079A (zh) 2018-03-13 2021-03-16 拉巴斯大学医院生物医学研究基金会 用于癌症免疫疗法的联合激活和扩增的自然杀伤细胞的抗cxcr4抗体
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2020146423A1 (en) 2019-01-07 2020-07-16 Thomas Jefferson University Multi-functional fusion proteins and uses thereof
WO2020198077A1 (en) * 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
WO2021183650A1 (en) 2020-03-10 2021-09-16 X4 Pharmaceuticals, Inc. Methods for treating neutropenia
AR129062A1 (es) 2022-04-13 2024-07-10 Genentech Inc Composiciones farmacéuticas de proteínas terapéuticas y métodos de uso
WO2023201291A1 (en) 2022-04-13 2023-10-19 Genentech, Inc. Pharmaceutical compositions of mosunetuzumab and methods of use
AR129203A1 (es) * 2022-05-04 2024-07-31 Janux Therapeutics Inc Anticuerpos multiespecíficos activados por tumores para dirigirse a cd28 y pd-l1, y métodos para usarlos
JP2026504180A (ja) * 2023-01-30 2026-02-03 カイマブ・リミテッド 抗体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2662383A1 (en) * 2008-08-25 2013-11-13 Amplimmune, Inc. PD-I antagonists and methods for treating infectious disease
CN103897058A (zh) * 2006-10-02 2014-07-02 梅达雷克斯有限责任公司 结合cxcr4的人类抗体及其用途
WO2015019284A2 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
ES2396220T3 (es) 2006-08-11 2013-02-20 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales frente al factor 1 derivado del estroma (SDF-1)
FR2915102B1 (fr) 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
KR20100133012A (ko) 2008-05-14 2010-12-20 일라이 릴리 앤드 캄파니 항-ｃｘｃｒ4 항체
US7892546B2 (en) 2008-05-14 2011-02-22 Eli Lilly And Company Anti-CXCR4 antibodies
EP2172485A1 (en) 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
WO2013013025A2 (en) 2011-07-20 2013-01-24 Medimmune Limited Anti-cxcr4 antibodies and methods of use
AU2012335553B2 (en) 2011-11-09 2017-09-21 Bristol-Myers Squibb Company Treatment of hematologic malignancies with an anti-CXCR4 antibody
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
CN104736168B (zh) 2012-05-31 2018-09-21 索伦托治疗有限公司 与pd-l1结合的抗原结合蛋白
WO2014089113A1 (en) 2012-12-03 2014-06-12 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
AR097102A1 (es) 2013-08-02 2016-02-17 Pfizer Anticuerpo anti-cxcr4 y conjugados de anticuerpo y fármaco

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103897058A (zh) * 2006-10-02 2014-07-02 梅达雷克斯有限责任公司 结合cxcr4的人类抗体及其用途
EP2662383A1 (en) * 2008-08-25 2013-11-13 Amplimmune, Inc. PD-I antagonists and methods for treating infectious disease
WO2015019284A2 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRISTOL-MYERS SQUIBB: "A phase1/2 study of the safety and efficacy of ulocuplumab combined with nivolumab in subjects with advanced or metastatic solid tumors", 《CLINICALTRIALS.GOV》 *
CHEN, YC等: "CXCR4 Inhibition in Tumor Microenvironment Facilitates Anti-Programmed Death Receptor-1 Immunotherapy in Sorafenib-Treated Hepatocellular Carcinoma in Mice", 《HEPATOLOGY》 *
FDA: "highlights of prescribing information—OPDIVO", 《FDA》 *
FEIG, CHRISTINE等: "Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer", 《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA》 *
GOH, YUN S等: "Human IgG isotypes and activating Fc gamma receptors in the interaction of Salmonella enterica serovar Typhimurium with phagocytic cells", 《IMMUNOLOGY》 *
公欣海等: "膀胱移行细胞癌组织B7-H1和CXCR4表达及其意义", 《齐鲁医学杂志》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164600A (zh) * 2018-10-17 2021-07-23 百欧林纳克斯有限公司 转移性胰脏腺癌的治疗
US12291570B2 (en) 2018-10-17 2025-05-06 Biolinerx Ltd. Treatment of metastatic pancreatic adenocarcinoma
WO2020135415A1 (zh) * 2018-12-24 2020-07-02 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途
CN113164599A (zh) * 2018-12-24 2021-07-23 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途
CN115487146A (zh) * 2022-10-28 2022-12-20 宁夏医科大学 一种阻断cxcr4/pd-l1双信号的三药共递送纳米体系及其制备方法和应用
WO2024120084A1 (zh) * 2022-12-07 2024-06-13 宜明昂科生物医药技术（上海）股份有限公司 使用cd24抗体和pd-1-pd-l1通路阻断抗体的癌症联合疗法
CN115960269A (zh) * 2023-01-30 2023-04-14 上海甲贝医药科技有限公司 一种重组长效人cxcr4&pd-1双靶点抗体融合蛋白及其制备方法

Also Published As

Publication number Publication date
EA201792522A1 (ru) 2018-05-31
WO2016201425A1 (en) 2016-12-15
MX2017015811A (es) 2018-04-10
EP3307778A1 (en) 2018-04-18
BR112017026189A2 (pt) 2018-08-14
JP2018516969A (ja) 2018-06-28
US20180179282A1 (en) 2018-06-28
WO2016201425A9 (en) 2017-01-19
CA2989144A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
CN108026173A (zh) 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症
US12083112B2 (en) Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
US11866509B2 (en) Humanized antibodies against CEACAM1
US20190382491A1 (en) Treatment of cancer using a combination of an anti-pd-1 antibody and anti-cd137
CN110536905B (zh) 用于治疗肺癌的抗pd-1抗体
US20190270812A1 (en) Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
US20230279096A1 (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
CN109890387A (zh) 谷氨酸调节剂与免疫疗法用以治疗癌症的用途
KR20250109796A (ko) 암을 치료하기 위한 pd-1 길항제 및 vegfr 억제제의 조합
CN109476752A (zh) 抗-pd-1抗体与抗-cd30抗体的组合在淋巴瘤治疗中的用途
CN109475634A (zh) 用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体
CN109641968A (zh) Tim-4拮抗剂和pd-1拮抗剂的组合及其使用方法
US20160264670A1 (en) Immunotherapeutic dosing regimens and combinations thereof
CN109475633A (zh) 在难治性霍奇金淋巴瘤中用纳武单抗阻断pd-1
JP7553439B2 (ja) がんを処置するための抗ｌａｇ３抗体の投薬レジメンおよび抗ｐｄ－１抗体との組み合わせ治療
US20240109972A1 (en) Antibody and taxane combination therapy
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
RU2771759C2 (ru) Антитела против pd-1 для лечения рака легких
HK1228930A1 (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
HK1232153B (en) Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180511

WD01 Invention patent application deemed withdrawn after publication